Cardiogen

Muscle/RecoveryKhavinson bioregulator / researchExperimental

Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): Low molecular weight peptide fraction
Half-life: Not established (limited PK data; primarily research context)
Unit: mg
Administration Route: Oral (capsule) or Subcutaneous in research contexts
Frequency: Once daily (typical research pattern)
Last updated: 8/23/2026
Targets: Cardiomyocytes (proposed)

Overview

Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.

Protocol

Dosage Range: 5-20 mg daily (research context; not clinically established)
Frequency: Once daily (typical research pattern)
Cycle: Common research cycles 10-30 days; varies by protocol
Administration Route: Oral (capsule) or Subcutaneous in research contexts
Reconstitution Guide: Reconstitute with bacteriostatic water if lyophilized (research only)

May vary by vendor concentration and protocol.

Science

Mechanism of Action

Claimed to modulate cardiomyocyte protein synthesis and gene expression in older bioregulator papers. Not validated in contemporary randomized trials.